News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 672 results
May 2019
-
Media ReleaseAveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families- One-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA- Annualized cost of Zolgensma is USD 425,000…
-
Media ReleaseAveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)- SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1,2]-…
-
Media ReleaseAveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
-
Media ReleaseAveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)
-
Media ReleaseNovartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders- Overall survival results from MONALEESA-7 with Kisqali® (ribociclib)* plus endocrine therapy in premenopausal women with HR+/HER2- advanced breast cancer, to be presented at ASCO- Primary results…
-
Media ReleaseFive nonprofit organizations to receive up to $250,000 through Novartis STEP Program™ to support sickle cell patient initiatives-The Solutions to Empower Patients (STEP) Program™ continues to help nonprofit organizations deliver new solutions to address unmet patient needs-This year's focus is on addressing some of the most…
-
Media ReleaseNovartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders
-
Media ReleaseFive nonprofit organizations to receive up to $250,000 through Novartis STEP Program™ to support sickle cell patient initiatives
-
Media ReleaseNovartis issues voluntary nationwide recall of Promacta® 12.5 mg for oral suspension due to potential peanut contamination- Voluntary recall of three lots issued after discovering potential cross contamination at a third-party manufacturer- Patients taking Promacta 12.5 mg for oral suspension should contact 1-866-918-…
-
Media ReleaseNovartis issues voluntary nationwide recall of Promacta® 12.5 mg for oral suspension due to potential peanut contamination
-
Media ReleaseNew AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1- Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial- Mean age of follow-up since dosing with…
Pagination
- ‹ Previous page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- …
- 56
- › Next page